ESMO 2016 consensus on treatment of advanced
mCRC
Progressive disease
Disease control
Cytoreduction
(shrinkage)
Progressive disease
Unusual,
see publication
CT + Avastin
CT + biological
agent
QT + Avastin
QT+ Avastin
Doublet +
anti-EGFR
Continue; maintenance,
or pause
Continue; maintenance,
or pause
Continue
BSC
2L
FP +/- Avastin
Reduced dose doublet
Anti-EGFR
Cure
Surgery alone
Surgery with
perioperative/
postoperative
CT
Clinical condition of the patient
Unfit (but may be suitable)
Unfit
Fit
Cytoreduction
Disease control
2L
Re-evaluation/assessment of response every 2-3 months
RAS WT
RAS MT
BRAF MT
RAS WT
RAS MT
BRAF MT
1. TR TAMIENTO DE
CONVERSIÓN
2. RÁPIDA REDUCCION
TUMORAL
